Abstract:The synthesis of a range of 3-hydroxy-4(1H)-pyridinones with potential for the chelation of iron(III) is described. The pK(a) values of respective ligands and the stability constants of their iron(III) complexes are presented, The distribution coefficient values of a range of 48 hydroxypyridinones and their corresponding iron(III) complexes between l-octanol and MOPS buffer (pH 7.4) are reported. The range of log D-complex values covers 7 orders of magnitude. The results suggest the existence of a biphasic relationship between the distribution coefficient values of the chelator and the corresponding iron(III) complexes. For ligands with a log D-ligand = -1, a linear relationship exists with a value of the slope 2.53, whereas with ligands with a log D-ligand < -1, a linear relationship exists with a slope of 0.49. The reduced slope for the more hydrophilic molecules of the series offers some advantage for this type of hydroxypyridinone as the distribution coefficients for such complexes do not change so rapidly with increasing ligand hydrophilicity. The ability of selected 3-hydroxypyridinones to facilitate the excretion of iron in bile was investigated in non-iron-overloaded, bile duct-cannulated rats and in a [Fe-59]ferritin-loaded rat model. Both systems compare the ability of chelators to remove iron from the liver, the prime target organ in thalassemia. The N-(hydroxyalkyl)-3-hydroxypyridin-4-ones are demonstrated to be orally active under the in vivo conditions adopted. Thus both 1-(hydroxyalkyl)- and 1-(carboxyalkyl)pyridinones are able to remove iron from the liver. Although 1-(carboxyalkyl)hydroxypyridinones are active, they do not demonstrate any clear advantage over Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one). Indeed 1-(hydroxyalkyl)hydroxypyridinones which are known to be rapidly converted to 1-(carboxyalkyl)hydroxypyridinones are also marginally superior to Deferiprone. In contrast, 2-ethyl-1-(2'-hydroxyethyl)-3-hyaroxypyridin-4-one, which is not metabolized to the corresponding (carboxyalkyl)hydroxypyridinone, was found to be superior to Deferiprone and therefore deserves further consideration as an orally active iron chelator with potential for the treatment of iron overload associated with transfusion-dependent thalassemia.

Design and Synthesis of Novel Pegylated Iron Chelators with Decreased Metabolic Rate

Synthesis, Physicochemical Properties, and Evaluation of<i>N</i>-Substituted-2-alkyl-3-hydroxy-4(1<i>H</i>)-pyridinones<sup>†</sup>

Synthesis and Biological Evaluation of Deferiprone-Resveratrol Hybrids As Antioxidants, Aβ1–42 Aggregation Inhibitors and Metal-Chelating Agents for Alzheimer's Disease

CN128: A New Orally Active Hydroxypyridinone Iron Chelator.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents

PEGylation of Deferoxamine for Improving the Stability, Cytotoxicity, and Iron-Overload in an Experimental Stroke Model in Rats

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption

Antioxidant targeting by deferiprone in diseases related to oxidative damage

Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

Design, Synthesis, and Biological Evaluation of New Improved Ferrostatin‐1 Derived Ferroptosis Inhibitors

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Design and Synthesis of 1,4‐Diformyl‐Piperazine Ferrostatin‐1 Derivatives as Novel Ferroptosis Inhibitors

Design, synthesis, and biological evaluation of 2-amino-6-methyl-phenol derivatives targeting lipid peroxidation with potent anti-ferroptotic activities

Synthesis and biological evaluation of ferrostatin-based diamide derivatives as new ferroptosis inhibitors

ATH434, a promising iron-targeting compound for treating iron regulation disorders

New polyazamacrocyclic 3-hydroxy-4-pyridinone based ligands for iron depletion antitumor activity

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.